性结肠炎治疗中的Dendrobium huoshanense:网络药理学和实验验证
Liang Yao1, Jing Fang2, Junwei Zhao2
1School of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012, Anhui, China; MOE-Anhui Joint Collaborative Innovation Center for Quality Improvement of Anhui Genuine Chinese Medicinal Materials, Hefei, 230012, Anhui, China.
Journal of ethnopharmacology
|January 8, 2024
概括
丹德罗 (Dendrobium huoshanense,DH) 通过调节炎性细胞因子和关键信号通路,有效治疗性结肠炎 (UC). 这项研究阐明了DH的治疗机制,为其在UC管理中的临床使用提供了基础.
科学领域:
- 药理学 药理学是指药理学的学科.
- 传统中国医药 传统中国医药
- 免疫学 免疫学 免疫学
背景情况:
- 丹德罗 (Dendrobium huoshanense,简称DH) 是一种传统的草药,有记录的胃肠道益处.
- 现代研究表明,DH调节肠道菌群,免疫力和消化分泌物.
- DH显示了性结肠炎 (UC) 的治疗潜力,但其机制需要阐明.
研究的目的:
- 研究Dendrobium huoshanense (DH) 在治疗性结肠炎 (UC) 的机制.
- 将网络药理与体内验证相结合,进行全面的分析.
主要方法:
- 网络药理学用于组件查,目标预测和途径分析 (GO,KEGG).
- 一个由3%的DSS诱导的UC小鼠模型被用于实验验证.
- 分析了关键目标和信号通路.
主要成果:
- 网络药理学确定了101个活性成分和314个潜在目标,其中SRC,STAT3,AKT1,HSP90AA1和PIK3CA是关键目标.
- 在UC小鼠中,DH治疗降低了促炎性细胞因子 (IL-6,TNF-α) 和增加了抗炎性细胞因子 (IL-10,TGF-β).
- DH改善了结肠长度和减少伤害,对SRC,STAT3,HSP90AA1,PIK3CA和PI3K/AKT通路进行上调.
结论:
- 这项研究使用网络药理学确定了用于UC治疗的DH的主要活性成分和点.
- 实验验证证证实了DH的抗炎作用和UC关键信号通路的调制.
- 这些发现为DH在治疗性结肠炎的临床应用提供了实验基础.
相关概念视频
01:17Drugs for Treatment of Diarrhea-Predominant IBS
176
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
176
01:29Drugs for Treatment of Ulcerative Colitis in IBD
142
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
142